11/28/2012

Merck & Co. cited business reasons in its decision to stop development of a diabetes pill that would have combined its Januvia and a generic version of Lipitor, Pfizer's cholesterol drug. Drugmakers see combination drugs as a way to reduce the number of medications patients take. Merck already markets Juvisync, which is Januvia plus the cholesterol drug simvastatin.

Full Story:
Reuters

Related Summaries